Bruker Reports First Quarter Financial Results
Bruker Corporation reported Q1 2022 revenues of $595.0 million, a 7.3% year-over-year increase. Organic revenue growth was notable at 10.5%. The company saw GAAP diluted EPS rise to $0.41, up from $0.37 in Q1 2021. With strong demand for its life science tools, Bruker raised its FY 2022 organic revenue outlook to 7% to 9% and expects non-GAAP EPS between $2.29 to $2.33, reflecting a 9% to 11% increase year-over-year. The firm also made key acquisitions to bolster growth.
- Q1 2022 revenue growth of 7.3% year-over-year.
- Organic revenue growth of 10.5% in Q1 2022.
- GAAP EPS increased to $0.41, up 10.8% year-over-year.
- Raised FY 2022 organic revenue growth guidance to 7% to 9%.
- Expected non-GAAP EPS between $2.29 and $2.33, a 9% to 11% increase year-over-year.
- Foreign currency transactions negatively impacted revenue growth by 4.2%.
- FY 2022 guidance includes foreign currency headwinds of approximately -3.5%.
-
Q1 2022 revenue growth of
7.3% year-over-year (yoy); organic revenue growth of10.5% -
Q1 2022 GAAP EPS
; non-GAAP EPS$0.41 , up$0.49 11.4% yoy - Raising fiscal year 2022 organic revenue outlook on strong demand for the Company’s high-performance life science tools, scientific instruments and diagnostic solutions
First Quarter 2022 Financial Results
Bruker’s revenues for the first quarter of 2022 were
First quarter 2022 Bruker Scientific Instruments (BSI) revenues of
First quarter 2022 GAAP operating income was
First quarter 2022 GAAP diluted earnings per share (EPS) were
A reconciliation of non-GAAP to GAAP financial measures is provided in the tables accompanying this press release.
He continued: “In the first quarter and in
Fiscal Year 2022 Financial Outlook
Bruker is increasing its FY 2022 organic revenue growth guidance to reflect strong demand for its high-performance life science tools, scientific instruments, and diagnostic solutions.
For FY 2022, Bruker expects
-
organic growth of
7% to9% , an increase of1% compared to prior guidance -
M&A contributions of approximately
1.5% , an increase of0.5% from prior guidance, and -
foreign currency translation headwinds of approximately -
3.5% , vs. prior guidance of -2% .
Consistent with prior guidance, in FY 2022, Bruker expects non-GAAP operating margin expansion of 30 bps to 60 bps from
Bruker continues to expect FY 2022 non-GAAP EPS of
Bruker’s organic revenue growth, non-GAAP operating margin expansion and non-GAAP EPS guidance for FY 2022 are based on foreign exchange rates as of
For the Company’s outlook for FY 2022, organic revenue growth, non-GAAP operating margin and non-GAAP EPS, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see “Use of Non-GAAP Financial Measures” below for a description of items excluded from our expected non-GAAP operating margin and non-GAAP EPS.
Quarterly Earnings Call
Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today,
About
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
Use of Non-GAAP Financial Measures
To supplement our consolidated financial statements, which are prepared and presented in accordance with
We also may refer to organic revenue growth or decline, free cash flow and return on invested capital, which are also non-GAAP financial measures. We define the term organic revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates and the effect of acquisitions and divestitures, and believe it is a useful measure to evaluate our continuing business. We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders. We define return on invested capital (ROIC) as non-GAAP operating profit after income tax divided by average total capital, which we define as debt plus equity minus cash and cash equivalents. We believe ROIC is an important measure of how effectively the Company invests its capital.
The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance; however, we urge investors to review the reconciliation of these financial measures to the comparable GAAP financial measures included in the accompanying tables, and not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance.
We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on certain non-GAAP measures and use this information for our planning and forecasting activities.
Additional information relating to the non-GAAP financial measures used in this press release and reconciliations to the most directly comparable GAAP financial measures are provided in the tables accompanying this press release following our GAAP financial statements.
With respect to our outlook for 2022 non-GAAP organic revenue, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP organic revenue, operating margin, tax rate and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future period operating margins, EPS and tax rate calculated and presented in accordance with GAAP.
Forward-Looking Statements
Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2022 financial outlook, our outlook for organic revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; management’s expectations for the impact of foreign currency and acquisitions, and for future financial and operational performance and business outlook; future economic conditions; the duration and impact of supply chain challenges; strategic investments; and statements found under the “Use of Non-GAAP Financial Measures” section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the length and severity of the COVID-19 pandemic, the impact of the pandemic on global economic conditions, the length and severity of any resulting recession, the impact of supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any resulting sanctions, continued volatility in the capital markets, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third-party distributors, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, exposure to foreign currency fluctuations, our ability to service our debt obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends and other risk factors discussed from time to time in our filings with the
-tables follow-
|
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) |
||||||||
(in millions) |
||||||||
|
|
|
|
|
|
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
816.1 |
|
|
$ |
1,068.2 |
|
Short-term investments |
|
|
100.0 |
|
|
|
100.0 |
|
Accounts receivable, net |
|
|
413.8 |
|
|
|
416.9 |
|
Inventories |
|
|
739.9 |
|
|
|
710.1 |
|
Assets held for sale |
|
|
— |
|
|
|
4.4 |
|
Other current assets |
|
|
196.7 |
|
|
|
172.2 |
|
Total current assets |
|
|
2,266.5 |
|
|
|
2,471.8 |
|
Property, plant and equipment, net |
|
|
403.8 |
|
|
|
406.1 |
|
|
|
|
896.1 |
|
|
|
772.1 |
|
Total assets |
|
$ |
3,566.4 |
|
|
$ |
3,650.0 |
|
|
|
|
|
|
|
|
||
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND
|
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Current portion of long-term debt |
|
$ |
11.0 |
|
|
$ |
112.4 |
|
Accounts payable |
|
|
161.2 |
|
|
|
147.4 |
|
Customer advances |
|
|
214.7 |
|
|
|
197.5 |
|
Other current liabilities |
|
|
509.3 |
|
|
|
481.2 |
|
Total current liabilities |
|
|
896.2 |
|
|
|
938.5 |
|
Long-term debt |
|
|
1,205.4 |
|
|
|
1,221.8 |
|
Other long-term liabilities |
|
|
426.7 |
|
|
|
404.9 |
|
|
|
|
|
|
|
|
||
Redeemable noncontrolling interest |
|
|
6.8 |
|
|
|
0.2 |
|
|
|
|
|
|
|
|
||
Total shareholders’ equity |
|
|
1,031.3 |
|
|
|
1,084.6 |
|
Total liabilities, redeemable noncontrolling interest and shareholders’ equity |
|
$ |
3,566.4 |
|
|
$ |
3,650.0 |
|
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) |
||||||||
(in millions, except per share data) |
||||||||
|
|
Three Months Ended
|
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Revenue |
|
$ |
595.0 |
|
|
$ |
554.7 |
|
Cost of revenue |
|
|
288.7 |
|
|
|
276.0 |
|
Gross profit |
|
|
306.3 |
|
|
|
278.7 |
|
Operating expenses: |
|
|
|
|
|
|
||
Selling, general and administrative |
|
|
145.7 |
|
|
|
131.8 |
|
Research and development |
|
|
56.6 |
|
|
|
54.8 |
|
Other charges, net |
|
|
7.5 |
|
|
|
3.0 |
|
Total operating expenses |
|
|
209.8 |
|
|
|
189.6 |
|
Operating income |
|
|
96.5 |
|
|
|
89.1 |
|
Interest and other income (expense), net |
|
|
(2.5 |
) |
|
|
(3.8 |
) |
Income before income taxes and noncontrolling interest in
|
|
|
94.0 |
|
|
|
85.3 |
|
Income tax provision |
|
|
31.9 |
|
|
|
27.5 |
|
Consolidated net income |
|
|
62.1 |
|
|
|
57.8 |
|
Net income attributable to noncontrolling interests in consolidated
|
|
|
0.5 |
|
|
|
1.1 |
|
Net income attributable to |
|
$ |
61.6 |
|
|
$ |
56.7 |
|
Net income per common share attributable to |
|
|
|
|
|
|
||
Basic |
|
$ |
0.41 |
|
|
$ |
0.37 |
|
Diluted |
|
$ |
0.41 |
|
|
$ |
0.37 |
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
||
Basic |
|
|
150.4 |
|
|
|
151.8 |
|
Diluted |
|
|
151.4 |
|
|
|
153.2 |
|
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) |
||||||||
(in millions) |
||||||||
|
|
Three Months Ended
|
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Consolidated net income |
|
$ |
62.1 |
|
|
$ |
57.8 |
|
Adjustments to reconcile consolidated net income to cash flows from operating
|
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
21.7 |
|
|
|
22.3 |
|
Stock-based compensation expense |
|
|
8.0 |
|
|
|
3.8 |
|
Deferred income taxes |
|
|
(4.0 |
) |
|
|
4.9 |
|
Other non-cash expenses, net |
|
|
(6.2 |
) |
|
|
4.9 |
|
Changes in operating assets and liabilities, net of acquisitions and divestitures: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
(2.4 |
) |
|
|
0.8 |
|
Inventories |
|
|
(49.0 |
) |
|
|
(41.6 |
) |
Accounts payable and accrued expenses |
|
|
(0.1 |
) |
|
|
35.5 |
|
Income taxes payable, net |
|
|
0.6 |
|
|
|
10.1 |
|
Deferred revenue |
|
|
22.7 |
|
|
|
14.1 |
|
Customer advances |
|
|
22.6 |
|
|
|
2.5 |
|
Other changes in operating assets and liabilities, net |
|
|
1.8 |
|
|
|
(17.1 |
) |
Net cash provided by operating activities |
|
|
77.8 |
|
|
|
98.0 |
|
Cash flows from investing activities: |
|
|
|
|
|
|
||
Cash paid for strategic investments at cost |
|
|
(12.0 |
) |
|
|
— |
|
Cash paid for acquisitions, net of cash acquired |
|
|
(83.8 |
) |
|
|
(4.0 |
) |
Purchases of property, plant and equipment |
|
|
(19.0 |
) |
|
|
(24.7 |
) |
Proceeds from sales of property, plant and equipment |
|
|
12.7 |
|
|
|
1.2 |
|
Net proceeds from cross currency swap agreements |
|
|
0.3 |
|
|
|
3.5 |
|
Net cash used in investing activities |
|
|
(101.8 |
) |
|
|
(24.0 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
||
Repayment of other debt, net |
|
|
(0.4 |
) |
|
|
(0.1 |
) |
Repayment of 2012 Note Purchase Agreement |
|
|
(105.0 |
) |
|
|
— |
|
Repayment of 2019 Note Purchase Agreement |
|
|
(0.8 |
) |
|
|
— |
|
Proceeds from issuance of common stock, net |
|
|
3.1 |
|
|
|
1.1 |
|
Payment of contingent consideration |
|
|
(1.2 |
) |
|
|
(0.4 |
) |
Payment of dividends to common stockholders |
|
|
(7.5 |
) |
|
|
(6.1 |
) |
Repurchase of common stock |
|
|
(105.6 |
) |
|
|
(32.6 |
) |
Net cash used in financing activities |
|
|
(217.4 |
) |
|
|
(38.1 |
) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
(10.7 |
) |
|
|
(21.0 |
) |
Net change in cash, cash equivalents and restricted cash |
|
|
(252.1 |
) |
|
|
14.9 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
1,071.7 |
|
|
|
685.5 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
819.6 |
|
|
$ |
700.4 |
|
|
||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES |
||||||||
(unaudited and in millions, except per share data) |
||||||||
|
||||||||
Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income and Non-
|
||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
GAAP operating income | $ |
96.5 |
|
$ |
89.1 |
|
||
Non-GAAP Adjustments: | ||||||||
Restructuring Costs |
|
0.4 |
|
|
2.4 |
|
||
Acquisition-Related Costs |
|
5.3 |
|
|
0.9 |
|
||
Purchased Intangible Amortization |
|
9.3 |
|
|
9.0 |
|
||
Other Costs |
|
4.3 |
|
|
0.8 |
|
||
Total Non-GAAP Adjustments: |
|
19.3 |
|
|
13.1 |
|
||
Non-GAAP operating income | $ |
115.8 |
|
$ |
102.2 |
|
||
Non-GAAP operating margin |
|
19.5 |
% |
|
18.4 |
% |
||
Non-GAAP Interest & Other Expense, net |
|
(4.2 |
) |
|
(3.8 |
) |
||
Non-GAAP Profit Before Tax |
|
111.6 |
|
|
98.4 |
|
||
Non-GAAP Income Tax Provision |
|
(36.5 |
) |
|
(30.6 |
) |
||
Non-GAAP Tax Rate |
|
32.7 |
% |
|
31.1 |
% |
||
Minority Interest |
|
(0.5 |
) |
|
(1.1 |
) |
||
Non-GAAP Net Income Attributable to Bruker |
|
74.6 |
|
|
66.7 |
|
||
Weighted average shares outstanding (diluted) |
|
151.4 |
|
|
153.2 |
|
||
Non-GAAP earnings per share | $ |
0.49 |
|
$ |
0.44 |
|
||
Reconciliation of GAAP and Non-GAAP Gross Profit | ||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
GAAP Gross Profit | $ |
306.3 |
|
$ |
278.7 |
|
||
Non-GAAP Adjustments: | ||||||||
Restructuring Costs |
|
0.1 |
|
|
1.1 |
|
||
Acquisition-Related Costs |
|
0.2 |
|
|
— |
|
||
Purchased Intangible Amortization |
|
4.5 |
|
|
4.5 |
|
||
Other Costs |
|
2.2 |
|
|
— |
|
||
Total Non-GAAP Adjustments: |
|
7.0 |
|
|
5.6 |
|
||
Non-GAAP Gross Profit | $ |
313.3 |
|
$ |
284.3 |
|
||
Non-GAAP Gross Margin |
|
52.7 |
% |
|
51.3 |
% |
||
Reconciliation of GAAP and Non-GAAP Selling, General and Administrative (SG&A) Expenses | ||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
GAAP SG&A Expenses | $ |
145.7 |
|
$ |
131.8 |
|
||
Non-GAAP Adjustments: | ||||||||
Purchased Intangible Amortization |
|
(4.8 |
) |
|
(4.5 |
) |
||
Non-GAAP SG&A Expenses | $ |
140.9 |
|
$ |
127.3 |
|
||
Reconciliation of GAAP Tax Rate to Non-GAAP Tax Rate |
||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
GAAP Tax Rate |
|
33.9 |
% |
|
32.2 |
% |
||
Non-GAAP Adjustments: | ||||||||
Tax Impact of Non-GAAP Adjustments |
|
-0.4 |
% |
|
-0.4 |
% |
||
Other Discrete Items |
|
-0.8 |
% |
|
-0.7 |
% |
||
Total Non-GAAP Adjustments: |
|
-1.2 |
% |
|
-1.1 |
% |
||
Non-GAAP Tax Rate |
|
32.7 |
% |
|
31.1 |
% |
||
Reconciliation of GAAP Earnings Per Share to Non-GAAP Earnings Per Share (Diluted) |
||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
GAAP Earnings Per Share (Diluted) | $ |
0.41 |
|
$ |
0.37 |
|
||
Non-GAAP Adjustments: | ||||||||
Restructuring Costs |
|
— |
|
|
0.02 |
|
||
Acquisition-Related Costs |
|
0.04 |
|
|
0.01 |
|
||
Purchased Intangible Amortization |
|
0.06 |
|
|
0.06 |
|
||
Other Costs |
|
0.01 |
|
|
0.01 |
|
||
Income Tax Rate Differential |
|
(0.03 |
) |
|
(0.03 |
) |
||
Total Non-GAAP Adjustments: |
|
0.08 |
|
|
0.07 |
|
||
Non-GAAP Earnings Per Share (Diluted) | $ |
0.49 |
|
$ |
0.44 |
|
||
Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow | ||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
GAAP Operating Cash Flow | $ |
77.8 |
|
$ |
98.0 |
|
||
Non-GAAP Adjustments: | ||||||||
Purchases of property, plant and equipment |
|
(19.0 |
) |
|
(24.7 |
) |
||
Non-GAAP Free Cash Flow | $ |
58.8 |
|
$ |
73.3 |
|
||
Reconciliation of Non-GAAP Return on |
||||||||
Trailing Twelve Months Ended |
||||||||
Non-GAAP operating income | $ |
483.8 |
|
|||||
Less: Non-GAAP income tax provision |
|
(132.0 |
) |
|||||
Non-GAAP operating income after tax | $ |
351.8 |
|
|||||
Average Long-Term Debt | $ |
962.7 |
|
|||||
Average Current Portion of Long-Term Debt |
|
59.7 |
|
|||||
Average Total Shareholder's Equity |
|
1,009.9 |
|
|||||
Less: Average Cash and Cash Equivalents |
|
756.5 |
|
|||||
$ |
1,275.9 |
|
||||||
Return on |
|
27.6 |
% |
|
||||||||
REVENUE |
||||||||
(unaudited and in millions) |
||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
Revenue by Group: | ||||||||
Bruker BioSpin | $ |
157.8 |
|
$ |
159.4 |
|
||
Bruker CALID |
|
203.2 |
|
|
192.4 |
|
||
|
178.5 |
|
|
154.4 |
|
|||
BEST |
|
59.7 |
|
|
52.4 |
|
||
Eliminations |
|
(4.2 |
) |
|
(3.9 |
) |
||
Total Revenue | $ |
595.0 |
|
$ |
554.7 |
|
||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
Revenue by End Customer Geography: | ||||||||
$ |
155.0 |
|
$ |
119.0 |
|
|||
|
201.9 |
|
|
219.9 |
|
|||
|
188.9 |
|
|
180.5 |
|
|||
Other |
|
49.2 |
|
|
35.3 |
|
||
Total Revenue | $ |
595.0 |
|
$ |
554.7 |
|
||
Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth |
||||||||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
Total Bruker |
||||||||
GAAP Revenue as of Prior Comparable Period | $ |
554.7 |
|
$ |
424.0 |
|
||
Non-GAAP Adjustments: | ||||||||
Acquisitions and divestitures |
|
5.8 |
|
|
3.2 |
|
||
Organic |
|
58.2 |
|
|
100.7 |
|
||
Currency |
|
(23.7 |
) |
|
26.8 |
|
||
Total Non-GAAP Adjustments: |
|
40.3 |
|
|
130.7 |
|
||
GAAP Revenue | $ |
595.0 |
|
$ |
554.7 |
|
||
Revenue Growth |
|
7.3 |
% |
|
30.8 |
% |
||
Organic Revenue Growth |
|
10.5 |
% |
|
23.8 |
% |
||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
Bruker Scientific Instruments (1) |
||||||||
GAAP Revenue as of Prior Comparable Period | $ |
506.2 |
|
$ |
381.5 |
|
||
Non-GAAP Adjustments: | ||||||||
Acquisitions and divestitures |
|
5.8 |
|
|
3.2 |
|
||
Organic |
|
48.0 |
|
|
97.7 |
|
||
Currency |
|
(20.5 |
) |
|
23.8 |
|
||
Total Non-GAAP Adjustments: |
|
33.3 |
|
|
124.7 |
|
||
GAAP Revenue | $ |
539.5 |
|
$ |
506.2 |
|
||
Revenue Growth |
|
6.6 |
% |
|
32.7 |
% |
||
Organic Revenue Growth |
|
9.5 |
% |
|
25.6 |
% |
||
Three Months Ended
|
||||||||
2022 |
2021 |
|||||||
BEST, net of Intercompany Eliminations |
||||||||
GAAP Revenue as of Prior Comparable Period | $ |
48.5 |
|
$ |
42.5 |
|
||
Non-GAAP Adjustments: | ||||||||
Organic |
|
10.2 |
|
|
3.0 |
|
||
Currency |
|
(3.2 |
) |
|
3.0 |
|
||
Total Non-GAAP Adjustments: |
|
7.0 |
|
|
6.0 |
|
||
GAAP Revenue | $ |
55.5 |
|
$ |
48.5 |
|
||
Revenue Growth |
|
14.4 |
% |
|
14.1 |
% |
||
Organic Revenue Growth |
|
21.0 |
% |
|
7.1 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005438/en/
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663–3660, ext. 1479
E: Investor.Relations@bruker.com
Source:
FAQ
What were Bruker's Q1 2022 earnings results?
How much did Bruker raise its organic revenue growth outlook for 2022?
What is Bruker's expected EPS for FY 2022?
What contributed to Bruker's revenue growth in Q1 2022?